Meeting Overview

We are excited to combine the historic Winter Lung Cancer Conference™ with the Miami Lung Cancer Conference® to offer you a world-class continuing medical education event for the treatment and incorporate the dynamic Medical Crossfire®, the traditional education format for the Winter Lung Cancer Conference™ and incorporate the dynamic Medical Crossfire®, exchange the Miami Lung is best known for.

Benefit of Attending This Year’s Meeting:

- Network with the expert faculty and your colleagues
- Hear about practice-changing data in lung cancers
- Unravel the complexity of emerging immunotherapy-based regimens
- Learn about optimizing the sequencing of targeted agents
- Get personalized advice from experts at Meet-the-Professor breakout sessions

Registration

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount.

**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 11.0 Contact Hours.
Agenda

Friday, January 25
6:30 PM Welcome Reception
7:15 PM Keynote Address
7:45 PM Moderated Q&A Session
8:00 PM Closing Remarks and Adjourn

Saturday, January 26
7:45 AM Welcome, Introductions, and Presession Survey

Module 1: Oncogenic Drivers: EGFR and ALK
8:00 AM First-Line Therapy for Patients With EGFR Mutation-Positive NSCLC
8:15 AM Moderated Q&A Session
8:20 AM Third-Generation EGFR Inhibitors: Mechanisms of Resistance and Treatment Options
8:35 AM Moderated Q&A Session
8:40 AM Interaction of EGFR Mutations and Immunotherapy: How to Bring Benefit to Patients
8:55 AM Moderated Q&A Session
9:00 AM ALK-Rearranged NSCLC: Choosing Therapy Through Multiple Lines of Treatment
9:15 AM Moderated Q&A Session
9:20 AM Postsession Survey
9:25 AM Panel Discussion
9:35 AM BREAK

Module 2: Oncogenic Drivers: The Growing Cohort
10:00 AM Postsession Survey
10:05 AM Approaches for ROS1 and BRAF: Current and Emerging Options
10:20 AM Moderated Q&A Session
10:25 AM Targeted Therapy for Emerging Oncogenic Drivers (Including RET, MET, HER2)
10:40 AM Moderated Q&A Session

10:45 AM Managing CNS Disease in Oncogene-Driven NSCLC
11:00 AM Moderated Q&A Session
11:05 AM Testing for Acquired Resistance: When and How?
11:20 AM Moderated Q&A Session
11:25 AM Panel Discussion

Module 3: Immunotherapy: Practical Applications - 1
11:35 AM Choosing First-Line Immunotherapy: Single-Agent or Combination in Nonsquamous NSCLC
11:50 AM Moderated Q&A Session
11:55 AM Choosing First-Line Immunotherapy: Single-Agent or Combination in Squamous NSCLC
12:10 PM Moderated Q&A Session
12:15 PM Mitigating and Managing Resistance to Immunotherapy
12:30 PM Moderated Q&A Session
12:35 PM Pushing the Envelope: Expanding Real-World Eligibility for Immunotherapy
12:50 PM Moderated Q&A Session
12:55 PM Postsession Survey
1:00 PM Panel Discussion
1:10 PM LUNCH

Module 4: Surgery, Radiation Therapy, and Other Issues
2:20 PM Presession Survey
2:25 PM Current Topics in Lung Cancer Surgery
2:40 PM Moderated Q&A Session
2:45 PM Best Practices for Radiation Therapy in Lung Cancer
3:00 PM Moderated Q&A Session
3:05 PM Managing Patients With Oligometastatic Disease
3:20 PM Moderated Q&A Session
3:25 PM Immunotherapy and Targeted Agents in the (Neo)Adjuvant Setting
3:40 PM Moderated Q&A Session
3:45 PM Postsession Survey
3:50 PM Panel Discussion
4:00 PM Closing Remarks and Adjourn

Sunday, January 27

Module 5: Practice of Oncology
7:45 AM Welcome, Introductions, and Presession Survey
8:00 AM Integrating Palliative Care in the Management of Patients With Lung Cancer
8:15 AM Moderated Q&A Session
8:20 AM Preparing for Alternative Reimbursement Models
8:35 AM Moderated Q&A Session
8:40 AM Panel Discussion

Module 6: Next Steps for Thoracic Malignancies
8:50 AM Immunotherapy Beyond PD-(L)1/CTLA-4
9:05 AM Moderated Q&A Session
9:10 AM Do We Have New Standards of Care for Patients With SCLC?
9:25 AM Moderated Q&A Session
9:30 AM Emerging Approaches for Mesothelioma
9:45 AM Moderated Q&A Session
9:50 AM Postsession Survey
9:55 AM Panel Discussion
10:05 AM BREAK

Module 7: Immunotherapy: Practical Applications - 2
10:30 AM Presession Survey
10:35 AM Integration of Immunotherapy in Unresectable Stage III NSCLC
10:50 AM Moderated Q&A Session
10:55 AM Management of Immune-Related Adverse Events
11:10 AM Moderated Q&A Session
11:15 AM With Immunotherapy Plus Chemotherapy, What Are the Roles of PD-L1 and TMB?
11:30 AM Moderated Q&A Session
11:35 AM Medical Crossfire®: For Patients With Stage IV NSCLC and PD-L1 ≥50%, Is the Standard of Care Immunotherapy Alone or Immunotherapy PlusChemotherapy?
11:50 AM Moderated Q&A Session
11:55 AM Postsession Survey
12:00 PM Panel Discussion
12:15 PM Closing Remarks and Adjourn

Agenda subject to change.

For more information and to register visit gotoper.com/go/WLC19TRI